Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resatorvid - Akaza Biopharma

Next Previous
Drug Profile

Resatorvid - Akaza Biopharma

Alternative Names: Compound(R)-(+)-5n; TAK 242; TAK-242 nanoparticle; TAK-242-NP; YAQ-005

Latest Information Update: 26 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akaza Bioscience
  • Developer Akaza Bioscience; Yaqrit
  • Class Anti-inflammatories; Small molecules; Sulfonamides
  • Mechanism of Action Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholic hepatitis; Liver failure
  • Preclinical Cutaneous T-cell lymphoma
  • No development reported Hyperammonaemia; Inborn urea cycle disorders
  • Discontinued Septic shock

Most Recent Events

  • 06 Dec 2025 Preclinical trials in Cutaneous T-cell lymphoma in United Kingdom (unspecified route) before December 2025
  • 06 Dec 2025 Pharmacodynamics data from preclinical studies in Cutaneous T-cell lymphoma were presented at 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 28 May 2025 No recent reports of development identified for preclinical development in Liver-failure(Prevention) in United Kingdom (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top